Laverdia (Verdinexor): FDA-Approved Oral Therapy for Canine Lymphoma

Verdinexor is an oral prescription antineoplastic for certain dogs with lymphoma. FDA announced full approval in January 2026 after the product's earlier conditional-approval pathway; publication should use the current label and naming.

Therapy class: Prescription oral antineoplastic; selective inhibitor of nuclear export

Form and route: Oral tablets

Verdinexor

Verdinexor is a selective inhibitor of nuclear export that blocks exportin 1/chromosome region maintenance 1 (XPO1/CRM1). FDA describes retention of tumor-suppressor and growth-regulating proteins in the nucleus, supporting control of cancer-cell growth and spread under the labeled canine lymphoma indication.

Manufacturer positioning: Current sponsor/brand materials position Laverdia as an at-home oral treatment for canine lymphoma. Directory must use the full FDA approval and current labeling rather than legacy CA1 claims or graphics.

The plan should define whether the objective is measurable remission, disease control or symptom benefit and how quickly lack of benefit or intolerance will trigger reassessment.

Before treatment, the team reviews diagnosis, prior drugs, blood counts, organ function, gastrointestinal status, concurrent medicines and safe tablet handling. Rechecks follow the current prescribing information.

Full FDA approval establishes substantial evidence for the labeled canine lymphoma indication under the approved conditions of use. It does not establish an indication in cats, every lymphoid cancer, every combination protocol or every country.

Decreased appetite, weight change, vomiting, diarrhea, lethargy and blood-count abnormalities require the prescribing team's monitoring plan. Seek urgent care for collapse, severe weakness, uncontrolled vomiting or diarrhea, bleeding, breathing difficulty or another clinic-defined emergency.

Share every prescription, over-the-counter medicine and supplement. Do not change corticosteroids, chemotherapy, anti-nausea medicine or supplement use, and do not alter tablets, without the oncologist's direction.

United States: FDA fully approved Laverdia under NADA 141-614 on 18 December 2025 for treatment of lymphoma in dogs. The prior Laverdia-CA1 conditional approval under application 141-526 is historical and should not remain the primary product name. This audit did not establish an EU, UK or Australian marketing authorisation.

Verified regulatory region: United States. Do not infer international approval from Dechra's global corporate presence.

Follow the current NADA 141-614 label and oncology plan. FDA materials call for frequent hematology and serum-chemistry monitoring and careful review of appetite, body weight, vomiting, diarrhea, lethargy, drinking/urination changes, liver enzymes and platelet counts. Cytotoxic handling controls apply to tablets, packaging, bowls and body waste; pregnant, potentially pregnant or nursing people and children require the label's exposure precautions. Treatment interruptions or changes belong to the prescriber.